![[ Beasley Allen Law Firm Logo ]](http://www.sjs-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}
TAMIFLU carries risk of serious adverse reaction
February 4th, 2009 by Jennifer Walker-Journey
Winter is the prime time for the flu. The Centers for Disease Control and Prevention recommends a yearly flu vaccine as the first and most important step in protecting against this serious disease. For those who don’t get the vaccine – and for some who do – influenza can occur.
The disease is a contagious respiratory illness. Symptoms usually start suddenly and may include a high fever, headache, tiredness, cough, sore throat, runny or stuffy nose, body aches and diarrhea and vomiting.
One way doctors help patients treat and prevent the flu is with TAMIFLU. Roache Laboratories, the company that makes TAMIFLU, says it is the No. 1 doctor-prescribed flu medication for the treatment of the flu for patients who have been symptomatic for no more than two days.
The medication is approved for both adults and children aged 1 year and older. But according to its safety labeling, and an announcement by the U.S. Chamber of Commerce, during post-marketing rare cases of Stevens Johnson Syndrome (SYS) and toxic epidermal necrolysis (TEN) have been reported by patients using TAMIFLU.
SJS and TEN are serious adverse reactions to medication. There are more than 200 types of medications that have been linked to SJS/TEN, most commonly ibuprofen, antibiotics and anti-seizure medication. The reaction begins with a rash on the skin that blisters over and causes the skin to peel off in sheets. Mucus membranes, such as the eyes and mouth, can blister over leading to serious health concerns such as dehydration, infection, blindness and even death. TEN is the most severe form of SJS, and carries a fatality risk of up to 30-40 percent.
Patients who experience a severe adverse reaction to medication they are taking are encouraged to contact their healthcare provider immediately or go to the emergency room.
